Clinical Data Inc., of Newton, Mass., reported results of two Phase I studies demonstrating that vilazodone, a dual-acting modulator of serotonin neurotransmission in development for the treatment of major depressive disorder, did not prolong the QT interval and that alteration of gastric pH does not adversely affect its pharmacokinetics...The results were presented in Anaheim, Calif., at the 2010 Midyear Clinical & Exhibition Meeting of the American Society of Health-System Pharmacists...The results
Gentium SpA, of Villa Guardia, Italy, presented clinical results for Defibrotide in patients veno-occlusive disease (VOD) and multi-organ failure (MOF) from several studies...Spectrum Pharmaceuticals Inc., of Irvine, Calif., presented Zevalin (ibritumomab tiuxetan) data as a preparatory or conditioning regimen prior to both allogeneic and autologous stem cell transplantation
BioCryst Pharmaceuticals Inc., of Birmingham, Ala., presented data that confirmed clinical activity of its drug forodesine in chronic lymphocytic leukemia...ChemGenex Pharmaceuticals Ltd., of Melbourne, Australia, presented updated clinical data showing that Omapro (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in a significant proportion of chronic phase chronic myeloid leukemia (CML) patients who had failed previous attempts to control their disease with two or
adult stem cells includes a collection, storage and processing service as well as a research and development unit for stem cell therapies, including VSEL technology acquired from the University of Louisville, in 2006...Cancer stem cell company Verastem Inc., of Boston, closed a $16 million Series A financing led by Longwood Founders Fund...Bessemer Venture Partners, Cardinal Partners and MPM Capital joined in the financing, which will be used by the company to advance discovery of stem cell therapies
By Catherine Shaffer | BioWorld Today | Wednesday, November 17, 2010
Stem Cells Inc., of Palo Alto, Calif., applied to Swissmedic, the Swiss drug regulatory agency, to conduct a trial of its human neural stem cell product, HuCNS-SC for spinal cord injury...Stem Cells' stock (NASDAQ:STEM) closed at $1.05, up 3 cents, on Monday
Stem Cell Therapeutics Corp., of Calgary, Alberta, filed a preliminary short form base shelf prospectus with Canadian securities commissions in British Columbia, Alberta, Manitoba, Ontario and Nova Scotia for offerings of common shares, warrants or units providing up to C$15 million (US$14,948,789) in aggregate over the next 25 months...The company plans to use the proceeds to fund ongoing R&D, working capital and general corporate activities, including clinical trials on its drug-based therapies
By Marie Powers | BioWorld Today | Friday, November 12, 2010
The firm plans to use the capital raised through the warrant exercises to strengthen its working capital reserves and for the expansion of its stem cell product development, including product development being undertaken at its subsidiaries Embryome Sciences Inc., OncoCyte Corp., OrthoCyte Corp., BioTime Asia Ltd...Common stock to be outstanding after the offering was 50.5 million shares.
By Marie Powers | BioWorld Today | Friday, November 5, 2010
Stem Cell Therapeutics Corp., of Calgary, Alberta, said that shareholders and brokers have completed the execution of 12,210,000 warrants with proceeds of C$1,822,000 (US$1,806,267...The funds will be used for ongoing research and development activities, working capital and general purposes including the company's clinical trial program. (See BioWorld Today, May 26, 2010.)
By Tom Wall | BioWorld Today | Thursday, November 4, 2010
StemCells Inc., of Palo, Calif., started a second clinical trial of HuCNS-SC, purified human neural stem cells, in Batten disease (neuronal ceroid lipofuscinosis), a fatal neurodegenerative disorder in children
and Germany, in which stem cell recipients at risk for developing HCMV viremia and disease are being treated prophylactically after transplantation. (See BioWorld Today, July 22, 2010, May 11, 2010, and April 15, 2010...The company said the next step in the clinical development of IMO-3100 will be a Phase II clinical trial in a selected autoimmune disease indication. (See BioWorld Today, Aug. 4, 2010
plc, of Dublin, Ireland, reported data further supporting the potential clinical use of an investigational assay detecting anti-JC virus antibodies in human plasma or serum, which may provide a means to segment multiple sclerosis patients receiving Tysabri (natalizumab) treatment...Neuralstem Inc., of Rockville, Md., said a safety monitoring board reviewed the first six patients treated in the company's ongoing Phase I trial of spinal cord stem cells for amyotrophic lateral sclerosis and allowed
NOX-A12, aimed at autologous stem cell transplantation in hematological disorders, has been evaluated in models of stem cell mobilization, angiogenesis, inflammation and lung and kidney injury...The first-in-human clinical trial for NOX-A12 was successfully completed in May in healthy individuals following intravenous administration of the drug candidate
By Catherine Hollingsworth | BioWorld Today | Wednesday, October 13, 2010
Geron Corp., of Menlo Park, Calif., initiated its Phase I trial of GRNOPC1, a human embryonic stem cell-derived oligodendrocyte progenitor cell therapy, for spinal cord injuries...The 24-to-30 patient study will evaluate safety, tolerability, pharmacokinetics and changes in MS clinical status
Advanced Cell Technology Inc., of Marlborough, Mass., completed Phase I trials in more than 40 patients testing its myoblast stem cell therapy in heart failure, advanced heart failure, myocardial infarction and ischemia...Results also demonstrated statistically significant improvements in clinical symptom scores and reductions in the incidence of bronchiolitis obliterans syndrome
No one should have to choose between participating in a clinical trial and accessing the essential benefits they need," said Rep...The award provides McLean Hospital and ACT's joint venture with CHA Biotech and Stem Cell & Regenerative Medicine International a $1.9 million prize to explore the potential of protein-induced pluripotent stem cells as a source of universal red blood cells and platelets for transfusion.
By Donna Young | BioWorld Today | Monday, September 27, 2010
Stem cell and gene therapy specialist Dabaghi Therapeutics Inc., of Houston, said it plans to conduct the world's first human cord blood stem cell treatment clinical trial via intramyocardial delivery
The firm, which boasts a platform designed to reprogram skin cells from patients into induced pluripotent stem cells, is working on neurological diseases, including spinal muscular dystrophy and amyotrophic lateral sclerosis...Proceeds from the financing will be used to advance lead candidates through clinical proof-of-concept studies
By Jennifer Boggs | BioWorld Today | Thursday, September 9, 2010
Bioheart's therapy involves the use of stem cells derived from the patient's own adipose tissue that are separated and later injected into the heart using the MyoCath needle injection catheter...FibroGen Inc., of San Francisco, reported results of a two-year clinical study demonstrating that surgical implantation of biosynthetic corneas formulated with the company's recombinant human type III collagen restored vision and promoted nerve regeneration (restoring sensitivity) in patients who had
Clinical Data Inc., of Newton, Mass., reported results of two Phase I studies demonstrating that vilazodone, a dual-acting modulator of serotonin neurotransmission in development for the treatment of major depressive disorder, did not prolong the QT interval and that alteration of gastric pH does not adversely affect its pharmacokinetics...The results were presented in Anaheim, Calif., at the 2010 Midyear Clinical & Exhibition Meeting of the American Society of Health-System Pharmacists...The results